Tokyo, Aug. 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062711) titled 'Establishment of a Dosimetry Protocol Using Post Pluvicto Treatment SPECT/CT Imaging' on Aug. 27.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Tokyo Medical University
Condition:
Condition - Castration-resistant prostate cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate whether the distribution of the radiopharmaceutical used for treatment actually matches that observed on the PSMA-PET scan performed to determine treatment eligibility.
Basic objectives2 - Bio-availability
Intervention:
Interventions/Control_1 - Radiation exposure associated with the concurrent use of a CT scan for fusion imaging during SPECT acquisition.
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male
Key inclusion criteria - Patients treated with Lutetium (177Lu) vipivotide tetraxetan
Key exclusion criteria - Patients unable to maintain the required body position for the necessary duration
Patients from whom consent cannot be obtained directly
Target Size - 10
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2026 Year 07 Month 29 Day
Date of IRB - 2026 Year 07 Month 29 Day
Anticipated trial start date - 2026 Year 08 Month 10 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071802
Disclaimer: Curated by HT Syndication.
